Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3885368 | 0.85 | THRB (0.55) | KMT2ATHRBKDM4EMEN1POLB | |
| Bromide SCHEMBL3884058 | 0.84 | KMT2A (0.74) | KMT2ATHRBKDM4EMEN1POLB | |
| SCHEMBL4895899 | 0.84 | GSK3B (0.54) | KMT2ATHRBKDM4EMEN1POLB | |
| Bromide SCHEMBL1645919 | 0.84 | KMT2A (0.73) | KMT2ATHRBKDM4EMEN1POLB | |
| SCHEMBL13394254 | 0.82 | KMT2A (0.70) | KMT2ATHRBKDM4EMEN1POLB | |
| Bromide SCHEMBL3884195 | 0.81 | KMT2A (0.70) | KMT2ATHRBKDM4EMEN1POLB | |
| Bromide SCHEMBL1645730 | 0.81 | KMT2A (0.70) | KMT2ATHRBKDM4EMEN1POLB | |
| SCHEMBL2230710 | 0.80 | KMT2A (0.68) | KMT2ATHRBKDM4EMEN1POLB | |
| SCHEMBL4896174 | 0.80 | KMT2A (0.68) | KMT2ATHRBKDM4EMEN1POLB | |
| Bromide SCHEMBL3885379 | 0.78 | KMT2A (0.66) | KMT2ATHRBKDM4EMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598352-A1 | 1-Glyoxylamide indolizines for treating cancer | Synta Pharmaceuticals Corporation (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1432709-B8 | 1-GLYOXYLAMIDE INDOLIZINES FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1432709-B1 | 1-GLYOXLYLAMIDE INDOLIZINES FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1537105-A2 | SYNTHESIS OF INDOLIZINES | Synta Pharmaceuticals Corporation (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6861436-B2 | 1-glyoxylamide indolizines for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040214850-A1 | 1-glyoxylamide indolizines for treating cancer | SYNTA PHARMACEUTICALS CORP. | 2004-10-28 | — | — | US | disclosed |
| US-20040152897-A1 | Synthesis of indolizines | SYNTA PHARMACEUTICALS CORP. (US) | 2004-08-05 | — | — | US | disclosed |
| EP-1432709-A1 | 1-GLYOXLYLAMIDE INDOLIZINES FOR TREATING CANCER | Synta Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004024727-A2 | SYNTHESIS OF INDOLIZINES | SYNTA PHARMACEUTICALS CORP. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20030153759-A1 | 1-Glyoxlylamide indolizines for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022846-A1 | 1-GLYOXLYLAMIDE INDOLIZINES FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214850-A1 | 1-glyoxylamide indolizines for treating cancer | NR2E1, NR4A1, NR0B1 | KMT2A 1211/4885THRB 664/4885KDM4E 2705/4885 |
| US-20040152897-A1 | Synthesis of indolizines | INMT, IDO1, IDO2 | KMT2A 783/4885THRB 4103/4885KDM4E 1552/4885 |
| US-20030153759-A1 | 1-Glyoxlylamide indolizines for treating cancer | NR4A1, NR0B1, NR2E1 | KMT2A 919/4885THRB 242/4885KDM4E 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.